Quick Answer
Nurix Therapeutics, Inc. reported Cash and Equivalents of $246.96 million for fiscal year 2025.
Nurix Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $246.96M | +124.5% |
| 2024 | $110.00M | +101.4% |
| 2023 | $54.63M | -15.3% |
| 2022 | $64.47M | -19.9% |
| 2021 | $80.51M | -32.5% |
| 2020 | $119.36M | +242.8% |
| 2019 | $34.82M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| August 31, 2025 | $78.44M | -20.8% | -6.9% |
| May 31, 2025 | $84.26M | -27.9% | +11.0% |
| February 28, 2025 | $75.92M | +52.4% | -31.0% |
| November 30, 2024 | $110.00M | +101.4% | +11.1% |
| August 31, 2024 | $99.04M | +134.1% | -15.2% |
| May 31, 2024 | $116.79M | +98.1% | +134.5% |
| February 29, 2024 | $49.81M | +48.4% | -8.8% |
| November 30, 2023 | $54.63M | -15.3% | +29.1% |
- Nurix Therapeutics, Inc. showed an increase of +124.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Nurix Therapeutics, Inc.’s cash and equivalents has grown by 609.3% (from $34.82 million to $246.96 million).
- The most recent figure is from Nurix Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 28, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: